These indications represent future expansion zones and a growing threat to narrowly targeted pipelines
There are no published studies specifically examining fatigue outcomes in MS patients treated with semaglutide, and clinical experience suggests variable individual responses
Primary and secondary outcomes included changes in HbA1c, body weight, and eating behavior patterns over 12 months
Yes, switching is straightforward since its the same medication
If youre considering Tirzepatide as part of your weight loss journey, we encourage you to schedule a consultation soon, as both medication and appointment availability are limited
At the same time, the drug development horizon is full of promising directions: oral formulations, multi-agonists, longer-acting molecules, and the emergence of biomarkers to personalize therapy